{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 50,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "key_takeaways",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/33",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.02,
        "y": 0.52
      },
      "kind": "callout",
      "text": "SPY002 could provide enhanced efficacy with improved coverage or further reduced dosing.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "127bb347-abb9-4f00-9c52-962e487fdeed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "list",
      "text": "Across many mechanisms in IBD, Phase 3 data were required to assess exposure-response. First-in-class anti-TL1A mAbs tested single induction regimen, providing insufficient evidence to select optimal dose.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9dcaebb-032e-4c4b-a3b0-a4c34a1f6beb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.02,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1. Rosario, M, et. al. (2017); Vedolizumab FDA Clinical Pharmacology Review. 2. In P2 studies, PRA023 dosed 1000mg IV on day 1, 500mg IV week 2, week 6, and week 10, followed by 100/250mg IV Q4W. P3 SC doses and frequency TBD. 3. Sands, B.E. et. al (2019); ustekinumab FDA Clinical Pharmacology Review. 4. Adedokun O.J., et. al. (2017). 5. Adedokun O.J., et. al. (2017). 6. Ponce-Bobadilla A.V., et. al. (2023).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b1ea8e7-4d14-4598-acb3-6f1169cab684",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.18
      },
      "kind": "table",
      "text": "Exposure-response relationships in IBD across MOAs",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c5edc67-1e02-48e0-876d-f6cd82e4f5a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Potential for further upside if sub-optimal dosing of first-generation anti-TL1A mAbs identified",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1293458b-89e0-4a2d-8811-89aab35f1e1e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}